Projet EGRET-Plus (Horizon 2020, appel à projets 2015)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Glaucoma is the most common age-related neurodegenerative eye-disease in western society and one of the four major blinding eye diseases. If untreated or detected too late, glaucoma will end in blindness, yielding a profound loss of quality of life for the individual and major costs to society. Given the vast complexity of glaucoma, to advance assessment and therapy beyond the current state-of-the-art, we need a new generation of researchers who are deeply knowledgeable about and intimately familiar with the many different approaches for study all aspects of glaucoma and the aging visual system: from functional test to anatomy, from gene to ganglion cell, from retina to brain. However, current knowledge is fragmented and so is the corresponding training. Very few researchers have been adequately trained which severely limits progress. Well-trained teams of dedicated glaucoma researchers are pivotal to integrate and extend the highly specialized knowledge, and to make a real difference for the patient. To overcome this problem, EGRET+ – the European Glaucoma Research Training Program Plus– has the aim of teaching young researchers in how to a) acquire new, quantitative knowledge on glaucoma and the aging visual system, and b) apply this new knowledge to boost innovation in glaucoma care in both the public and private sectors. This will: 1) enable the development of new tools for the early detection and cost-effective monitoring of glaucoma; 2) inspire the development and implementation of new treatments; 3) contribute to our understanding of the relationships between various neurodegenerative diseases, and 4) contribute to improving healthy aging in general. This new knowledge therefore has tremendous potential to positively impact the lives of millions of European citizens.

Mots clés : glaucoma, ophthalmology, neurodegeneration, intracranial pressure, intraocular pressure, visual fields, brain, visual pathways, translational genetics, neuro imaging, electrophysiology, fmri

Participants :
- Heidelberg Engineering (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Implandata Ophthalmic Products (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 249216.48 €
- Ocuspecto oy (Finlande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 269145.36 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 255374.28 €
- Australian National University (Australie) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Eurogrant gmbh (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Turku (Finlande) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Otto-von-Guericke University Magdeburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 747649.44 €
- Stichting koninklijke visio, expertisecentrum voor slechtziende en blinde mensen (Pays-Bas) — Partner, organization partner, Autres, subvention : 0.0 €
- University Medical Center Groningen (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 1276871.4 €
- University of London (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 546575.76 €
- Université Clermont Auvergne (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 262875.6 €
- Echodia (France) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 262875.6 €
- Amo groningen bv (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €